argenx, which is developing antibody therapies for rare autoimmune diseases and cancer, raised $100 million by offering 5.9 million ADSs at $17. argenx plans to list on the Nasdaq under the symbol ARGX. Cowen & Company and Piper Jaffray acted as lead managers on the deal.
